Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study
暂无分享,去创建一个
T. Naoe | T. Nagai | C. Nakaseko | K. Miyamura | Y. Miyazaki | A. Matsuda | K. Ohyashiki | A. Tojo | K. Oritani | T. Kawaguchi | M. Okada | S. Okamoto | Y. Maeda | Hideo Tanaka | Yukio Kobayashi | K. Usuki | N. Usui | Taro Amagasaki | Aira Wanajo | Y. Kobayashi